Site Editor

Sandy Srinivas, MD

Advertisement

Advertisement

Medical Literature

Can Deep Learning Provide Assistance in Assessing Treatment Response in Advanced Prostate Cancer?

News

AUA 2023: Update on Novel Radioligand Therapy for Castration-Resistant Prostate Cancer

News

AUA 2023: Patients’ Preferences Take Center Stage in Study of Androgen-Deprivation Therapy

News

AUA 2023: ARAMIS Trial Update on Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer

News

AUA 2023: How Does AI Model Compare With Radiologists in Detecting Prostate Cancer on MRI?

Medical Literature

Prostate Cancer, Multiple Myeloma, and CML: A Rare Triple Combination in a Single Patient

News

AACR 2023: Does Inflammation Tie Together Prostate Cancer, Colorectal Cancer, and Ulcerative Colitis?

Scott T. Tagawa, MD, on Clinical Implications of Using an Anti-PSMA Antibody With Ketoconazole, Hydrocortisone, and Lutetium-177 in Treatment of Prostate Cancer

Neal D. Shore, MD, on New Data on the Safety and Efficacy of Darolutamide in Patients With Prostate Cancer

View More

Advertisement

JNCCN Spotlights

Lutetium Lu-177 Vipivotide Tetraxetan

(UPDATE September 2022) Enzalutamide

(UPDATE) Degarelix (Injectable GnRH Antagonist)

Docetaxel (Castration-Naive Metastatic Prostate Cancer)

UPDATE October 2020 Enzalutamide

Degarelix (Injectable GnRH Antagonist)

(UPDATE) Apalutamide in Prostate Cancer

View More

More

News

Transgender Women May Be at Risk for Prostate Cancer, Study Reveals

Prostate Cancer Screening Practices in Transgender Patients

ASCO GU 2023: PSA Response to Darolutamide Monotherapy in Hormone-Naive Prostate Cancer

Is Nadir PSA Value an Independent Predictor of Survival in Prostate Cancer?

AUA 2023: Risk of Cardiovascular Events After Androgen-Deprivation Therapy for Prostate Cancer

ASCO GU 2023: Talazoparib Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

RALU Study: Impact of Sequencing Radionuclide Therapies on Outcomes in Prostate Cancer

ASCO GU 2023: Hormone Therapy Plus an Anti-PSMA Antibody Labeled With Lu-177 in Nonmetastatic Prostate Cancer

View More

Advertisement

Published

Medical Literature

Researchers Offer Evidence That Prostate Cancer Biology May Differ by Racial Ancestry

Adding Darolutamide to Standard Treatment in Metastatic, Hormone-Sensitive Prostate Cancer

Enzalutamide Monotherapy: Active Surveillance Alternative in Low- or Intermediate-Risk Prostate Cancer?

Can the Number of Positive Pelvic Lymph Nodes Guide Adjuvant Radiation Therapy for Prostate Cancer?

View More

Ongoing

CE Activities

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Prostate Cancer

Genitourinary Cancers: Assessing the Roles of Immune-Based and Targeted Therapies in a Changing Treatment Landscape

Oncology Today with Dr Neil Love: Key Presentations on Genitourinary Cancers from the 2022 ASCO Annual Meeting

Talk to Someone: Explore Talking to Patients About Prostate Cancer Treatment

View More

Available

Clinical Trials

Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC (CONTACT-02)

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

View More

Resources

For Your Patients

Prostate Health Education Network

Urology Care Foundation

Cancer Support Community

Prostate Cancer Foundation

View More

Sections

360 Hub

NCCN Resources

Copyright^© 2023 National Comprehensive Cancer Network, All Rights Reserved

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.